195 related articles for article (PubMed ID: 14966093)
21. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
[TBL] [Abstract][Full Text] [Related]
22. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous detection of multiple mRNA markers CK19, CEA, c-Met, Her2/neu and hMAM with membrane array, an innovative technique with a great potential for breast cancer diagnosis.
Chen CC; Hou MF; Wang JY; Chang TW; Lai DY; Chen YF; Hung SY; Lin SR
Cancer Lett; 2006 Aug; 240(2):279-88. PubMed ID: 16289546
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the immunohistochemical expression of mammaglobin A in primary breast carcinoma and lymph node metastasis.
Raica M; Cîmpean AM; Meche A; Alexa A; Suciu C; Mureşan A
Rom J Morphol Embryol; 2009; 50(3):341-7. PubMed ID: 19690758
[TBL] [Abstract][Full Text] [Related]
25. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
[TBL] [Abstract][Full Text] [Related]
26. Mammaglobin, a potential marker of breast cancer nodal metastasis.
Leygue E; Snell L; Dotzlaw H; Hole K; Troup S; Hiller-Hitchcock T; Murphy LC; Watson PH
J Pathol; 1999 Sep; 189(1):28-33. PubMed ID: 10451484
[TBL] [Abstract][Full Text] [Related]
27. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer.
Yang DC; Wang F; Elliott RL; Head JF
Anticancer Res; 2001; 21(1B):541-9. PubMed ID: 11299801
[TBL] [Abstract][Full Text] [Related]
28. Signal transducer and activator of transcription-5 activation and breast cancer prognosis.
Nevalainen MT; Xie J; Torhorst J; Bubendorf L; Haas P; Kononen J; Sauter G; Rui H
J Clin Oncol; 2004 Jun; 22(11):2053-60. PubMed ID: 15169792
[TBL] [Abstract][Full Text] [Related]
29. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Kawaguchi M; Miura Y; Iwase H
Clin Cancer Res; 2005 Jan; 11(1):193-8. PubMed ID: 15671546
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
[TBL] [Abstract][Full Text] [Related]
31. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
32. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
33. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
[TBL] [Abstract][Full Text] [Related]
34. HDAC6 expression is correlated with better survival in breast cancer.
Zhang Z; Yamashita H; Toyama T; Sugiura H; Omoto Y; Ando Y; Mita K; Hamaguchi M; Hayashi S; Iwase H
Clin Cancer Res; 2004 Oct; 10(20):6962-8. PubMed ID: 15501975
[TBL] [Abstract][Full Text] [Related]
35. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
36. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
[TBL] [Abstract][Full Text] [Related]
37. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
Jansen MP; Sieuwerts AM; Look MP; Ritstier K; Meijer-van Gelder ME; van Staveren IL; Klijn JG; Foekens JA; Berns EM
J Clin Oncol; 2007 Feb; 25(6):662-8. PubMed ID: 17308270
[TBL] [Abstract][Full Text] [Related]
38. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.
Mulligan AM; O'Malley FP; Ennis M; Fantus IG; Goodwin PJ
Breast Cancer Res Treat; 2007 Nov; 106(1):39-47. PubMed ID: 17221153
[TBL] [Abstract][Full Text] [Related]
39. The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients.
Bièche I; Parfait B; Noguès C; Andrieu C; Vidaud D; Spyratos F; Lidereau R; Vidaud M
Oncogene; 2001 Oct; 20(47):6955-9. PubMed ID: 11687975
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
